CN104771368A - Cefpodoxime proxetil rapid-release preparation and preparation method thereof - Google Patents
Cefpodoxime proxetil rapid-release preparation and preparation method thereof Download PDFInfo
- Publication number
- CN104771368A CN104771368A CN201510163430.XA CN201510163430A CN104771368A CN 104771368 A CN104771368 A CN 104771368A CN 201510163430 A CN201510163430 A CN 201510163430A CN 104771368 A CN104771368 A CN 104771368A
- Authority
- CN
- China
- Prior art keywords
- mixture
- release solid
- essence
- preparation
- cefpodoxime proxetil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a cefpodoxime proxetil rapid-release solid preparation and a preparation method thereof. The cefpodoxime proxetil rapid-release solid preparation comprises cefpodoxime proxetil and a surfactant, wherein cefpodoxime proxetil accounts for 2.5-15wt% of the total preparation, and the surfactant accounts for 0.8-15.0wt% of the total preparation. The method for preparing the rapid-release solid preparation adopts wet granulation and specifically comprises the following steps: (1) dissolving cefpodoxime proxetil and the surfactant in absolute ethyl alcohol to obtain a mixture I; (2) after mixing a diluting agent with a disintegrating agent uniformly, slowly adding or spraying the mixture I and carrying out granulation and fluidized bed drying to obtain a mixture II; (3) adding a suspending aid, a flavoring agent and a lubricating agent to the mixture II and carrying out total mixing and subpackaging. The rapid-release solid preparation can be quickly dissolved out when meeting water and can not be gelated. Meanwhile, technology improvement is adopted, thus avoiding the processes of raw material grinding and micronization treatment; and special equipment, such as a dry type granulator, is unnecessary to be used, thus ensuring the product stability while simplifying the production operation.
Description
Technical field
The invention belongs to medical art, particularly relate to a kind of Cefpodoxime Proxetil fast release solid formulation and preparation method thereof.
Background technology
Cefpodoxime Proxetil chemical name: (6R, 7R)-7-[2-(thiazolamine-4-base)-2-(Z)-(methoxyimino)-acetamido]-3-methoxyl methyl-8-oxo-5-sulfur-1-azabicyclo-[4,2,0] oct-2-ene-2-formic acid isopropyl oxygen carbonyl oxygen ethyl ester, its structural formula is:
Molecular formula: C
21h
27n
5o
9s
2
CAS：87239-81-4
Cefpodoxime Proxetil commodity are called: VANTIN, are the oral broad-spectrum cephalosporins of the third generation of Japan's exploitation, on August 7th, 1992 Cefpodoxime Proxetil tablet and dry suspension have passed the application for quotation of FDA, go on the market in the U.S..Cefpodoxime Proxetil is the third generation cephalosporin possessing has a broad antifungal spectrum, long half time, the advantage such as easy to use, cross resistance is less, dosage is few, and clinical being mainly used in treats responsive microbial infection.
Cefpodoxime Proxetil is the prodrug of cefpodoxime, and itself through intestinal absorption after oral without antibacterial activity, become cefpodoxime at intestinal wall by nonspecific esterase hydrolyzed and play antibacterial activity.Cefpodoxime has very high affinity to specificity penicillin-binding protein 1,3.There is the cefpodoxime of antibacterial activity, bacteria cell wall synthesis can be affected, cause cytolysis.
Cefpodoxime Proxetil is white or pale yellow powder, odorless or micro-ly have special odor.Very easily dissolve in acetonitrile or methanol, easily molten in dehydrated alcohol, almost insoluble in water, meet water unstable and in gel, have a strong impact on the dissolution velocity of medicine.According to Biopharmaceutics Classification system, belong to BCS IV class.
Cefpodoxime proxetil suspension Yuan Yan producer is pharmaceutical Co. Ltd altogether of Japan the one or three, and its 15 minutes dissolution in water, pH1.2 hydrochloric acid medium, pH4.0 acetate buffer and pH6.8 phosphate buffer is greater than 85%.The dissolution of Cefpodoxime proxetil suspension in above-mentioned four kinds of dissolution mediums of domestic current listing is inconsistent, and great majority can not reach the result of extraction consistent with former triturate, therefore on market in the urgent need to a kind of Cefpodoxime Proxetil fast release solid formulation.
The patent CN1681497 of Ranbaxy Lboratories Ltd. of India application discloses a kind of preparation method of beta-Lactam antibiotic oral cavity disintegration tablet, and it adopts the method for aqueous granulation to prepare oral cavity disintegration tablet medicine and disintegrating agent.
The patent CN1505515 of Ranbaxy Lboratories Ltd. of India application discloses a kind of stabilizing pharmaceutical composition of Cefpodoxime Proxetil of oral medication, it will control particle diameter and specific surface area after drug micronization, make Drug absorbability on particular polymers surface by special equipment again, thus improve the dissolution of medicine.
The patent CN 102525948 of SHANDONG LUOXIN PHARMACY STOCK Co., LTD.'s application discloses a kind of Cefpodoxime proxetil suspension and preparation method thereof, and raw material first mixes with all the other adjuvants by the method, then granulates as wetting agent with 95% ethanol, avoids medicine to lump.
The patent CN 103230367 of SHANDONG LUOXIN PHARMACY STOCK Co., LTD.'s application discloses a kind of Cefpodoxime proxetil suspension and preparation method thereof, raw material first mixes with all the other adjuvants by the method, granulate as binding agent with starch slurry again, avoid medicine to lump, and strengthen the antibacterial effect of Cefpodoxime Proxetil.
The patent CN100571683 of Shenzhen Zhijun Pharmaceutical Co., Ltd's application discloses a kind of dry suspension and preparation method thereof, excipient is added to the water and obtains suspending medium by this preparation method, add active fraction preparation medicine suspension solution again, object avoids caking, reduces production cost.
Although prior art improves medicine caking phenomenon, but still it is on the low side to there is preparation dissolution, raw material needs special handling or the loaded down with trivial details problem of production process, therefore need to find one or more adjuvants, adopt a kind of simple preparation technology, overcome prior art deficiency, to increase drug dissolution and dissolution rate, while simplifying production operation, ensure product stability.
Summary of the invention
The object of this invention is to provide a kind of Cefpodoxime Proxetil fast release solid formulation and preparation method thereof, be gel state to solve existing Cefpodoxime Proxetil fast release solid formulation technology Raw chance water, preparation dissolution is on the low side; Raw material need special handling and dry granulation high to equipment requirements, the problem that production process is loaded down with trivial details.
Containing Cefpodoxime Proxetil in Cefpodoxime Proxetil fast release solid formulation of the present invention, also reach the necessary surfactant of the object of the invention, diluent, disintegrating agent, suspending agent and lubricant containing promising, it is characterized in that, each composition is by total formulation weight gauge:
Preferably, fast release solid formulation of the present invention, each composition is by total formulation weight gauge:
In fast release solid formulation of the present invention, the weight ratio of surfactant and Cefpodoxime Proxetil is 1:1 ~ 1:3, preferred 1:2 ~ 1:3, more preferably 1:2.
In fast release solid formulation of the present invention, surfactant is non-ionic surface active agent, be selected from the mixture of one or more of Tweens, spans, polyoxyethylene apoplexy due to endogenous wind, it can be one or more mixture in polysorbas20, polysorbate40, polysorbate60, Tween 80, polysorbate85, span 20, span 40, sorbester p18, sorbester p17, sorbester p37, polyoxyethylene castor oil, polyoxyethylene hydrogenated Oleum Ricini and poloxamer, a kind of or both mixture in preferred polyoxyethylene castor oil and polyoxyethylene hydrogenated Oleum Ricini, more preferably polyoxyethylene hydrogenated Oleum Ricini.
Diluent to be selected from sucrose, Lactis Anhydrous, mannitol, soluble starch one or more mixture, one or both mixture in preferred Lactis Anhydrous and sucrose;
Disintegrating agent to be selected from low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethylcellulose calcium one or more mixture, preferably carboxymethyl cellulose calcium;
Suspending agent to be selected from hyprolose, hypromellose, polyvidone, sodium carboxymethyl cellulose and xanthan gum one or more mixture, preferred xanthan gum;
Lubricant agent is selected from the mixture of one or more in silicon dioxide, Pulvis Talci, magnesium stearate, stearic acid, Polyethylene Glycol, sodium stearyl fumarate, Glyceryl Behenate and hydrogenated vegetable oil, preferably talc powder.
Also containing correctives in fast release solid formulation of the present invention, correctives is the mixture of acidity regulator and essence.Acidity regulator is selected from the mixture of one or more in citric acid, malic acid, tartaric acid, preferably citric acid; Essence is selected from the mixture of one or more in flavoring banana essence, flavoring orange essence, Fructus Citri Limoniae essence, peach flavor, cream flavour, chocolate essence, strawberry essence, flavoring pineapple essence, apple essence, kiwi flavor, grape essence, watermelon essence, Hami melon essence, preferred flavoring orange essence.
Another object of the present invention is to the preparation method providing a kind of Cefpodoxime Proxetil fast release solid formulation, its preparation technology is wet granulation, and the equipment of use is wet mixing pelletizer or fluid bed.Concrete operations are:
(1) Cefpodoxime Proxetil and surfactant are dissolved in dehydrated alcohol, obtain mixture one;
(2) by after diluent and disintegrating agent mix homogeneously, slowly add or spray into mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two;
(3) in mixture two, add suspending agent, correctives and lubricant, always mix, subpackage.
Fast release solid formulation of the present invention is applicable to oral drug preparation, can be Oral Dry Suspensions and granule etc.Raw material and surfactant are dissolved in dehydrated alcohol altogether, after drying of granulating, Cefpodoxime Proxetil and surfactant are dispersed in particle surface and inside, when this pharmaceutical preparation joins aqueous dissolution medium, water soluble adjuvant and part Cefpodoxime Proxetil rapid solution, surfactant then can be distributed in rapidly the surface remaining non-dissolved substance, its distinctive hydrophilic group outwards stretches bound water molecule, hydrophobic group is enclosed in Cefpodoxime Proxetil molecular surface, drug molecule is separated one by one, thus can effectively avoid medicine to produce the trend of gelation, accelerate the dissolving of Cefpodoxime Proxetil.
The present invention, by Cefpodoxime Proxetil is dissolved in dehydrated alcohol, eliminates in prior art and uses special installation by raw material micronization, and then by raw material in the troublesome operation of special installation internal adsorption on adjuvant surface; Use dehydrated alcohol as wetting agent, whole preparation process avoids the introducing of moisture, ensures the stability of medicine.The use of surfactant, effectively prevent Cefpodoxime Proxetil and meets aqueous gelled trend, substantially increase the dissolution of preparation.
Accompanying drawing explanation
Preparation (embodiment 1 ~ 3 and comparative example 2 ~ 3) the stripping curve comparison diagram in purified water of Fig. 1 different surfaces activating agent consumption.
Fig. 2 uses preparation (embodiment 2 and 4) the stripping curve comparison diagram in purified water of different wet granulation equipment.
Fig. 3 embodiment 2 and comparative example 1 stripping curve comparison diagram in purified water.
Fig. 4 embodiment 2 and comparative example 1 stripping curve comparison diagram in pH1.2 hydrochloric acid medium.
Fig. 5 embodiment 2 and comparative example 1 stripping curve comparison diagram in pH4.0 acetate media.
Fig. 6 embodiment 2 and comparative example 1 stripping curve comparison diagram in pH6.8 phosphate medium.
Table 1 embodiment 2 accelerated test comparing result.
Detailed description of the invention
By the following examples the present invention is described in further detail.But the present invention is not limited to these examples.
Embodiment 1 (1000 bags of amounts)
Preparation process:
(1) get recipe quantity Cefpodoxime Proxetil and polyoxyethylene hydrogenated Oleum Ricini is dissolved in dehydrated alcohol, obtain mixture one.
(2) put in fluid bed after mix homogeneously by Lactis Anhydrous, sucrose and carboxymethylcellulose calcium, slowly spray into mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two.
(3) in mixture two, add xanthan gum, citric acid, Pulvis Talci and flavoring orange essence, always mix, subpackage.
Embodiment 2 (1000 bags of amounts)
Preparation process:
(1) get recipe quantity Cefpodoxime Proxetil and polyoxyethylene hydrogenated Oleum Ricini is dissolved in dehydrated alcohol, obtain mixture one.
(2) put in fluid bed after mix homogeneously by Lactis Anhydrous, sucrose and carboxymethylcellulose calcium, slowly spray into mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two.
(3) in mixture two, add xanthan gum, citric acid, Pulvis Talci and flavoring orange essence, always mix, subpackage.
Embodiment 3 (1000 bags of amounts)
Preparation process:
(1) get recipe quantity Cefpodoxime Proxetil and polyoxyethylene hydrogenated Oleum Ricini is dissolved in dehydrated alcohol, obtain mixture one.
(2) put in fluid bed after mix homogeneously by Lactis Anhydrous, sucrose and carboxymethylcellulose calcium, slowly spray into mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two.
(3) in mixture two, add xanthan gum, citric acid, Pulvis Talci and flavoring orange essence, always mix, subpackage.
Embodiment 4 (1000 bags of amounts)
Preparation process:
(1) get recipe quantity Cefpodoxime Proxetil and polyoxyethylene hydrogenated Oleum Ricini is dissolved in dehydrated alcohol, obtain mixture one.
(2) put in wet mixing pelletizer after mix homogeneously by Lactis Anhydrous, sucrose and carboxymethylcellulose calcium, slowly add mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two.
(3) in mixture two, add xanthan gum, citric acid, Pulvis Talci and flavoring orange essence, always mix, subpackage.
For convenience of contrasting with embodiment, spy enumerates following comparative example, carries out comparative study.
Comparative example 1 (1000 bags of amounts)
Preparation process:
Get Cefpodoxime Proxetil and sucrose mistake 100 mesh sieves respectively, 120 mesh sieves are for subsequent use excessively respectively to get hypromellose, xanthan gum; Get the Cefpodoxime Proxetil 50g of pulverizing and the sucrose 660g mix homogeneously of pulverizing, add 95% ethanol 200g soft material, then 40 mesh sieves are granulated, and obtained wet granular, 45 ~ 50 DEG C of dryings 30 minutes, crosses 40 mesh sieve granulate; Obtained dry granule is mixed with the hypromellose 71g of pulverizing and the xanthan gum 71g of pulverizing, to obtain final product.
Comparative example 2 (1000 bags of amounts)
Preparation process:
(1) get recipe quantity Cefpodoxime Proxetil and polyoxyethylene hydrogenated Oleum Ricini is dissolved in dehydrated alcohol, obtain mixture one.
(2) put in fluid bed after mix homogeneously by Lactis Anhydrous, sucrose and carboxymethylcellulose calcium, slowly spray into mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two.
(3) in mixture two, add xanthan gum, citric acid, Pulvis Talci and flavoring orange essence, always mix, subpackage.
Comparative example 3 (1000 bags of amounts)
Preparation process:
(1) get recipe quantity Cefpodoxime Proxetil and polyoxyethylene hydrogenated Oleum Ricini is dissolved in dehydrated alcohol, obtain mixture one.
(2) put in fluid bed after mix homogeneously by Lactis Anhydrous, sucrose and carboxymethylcellulose calcium, slowly spray into mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two.
(3) in mixture two, add xanthan gum, citric acid, Pulvis Talci and flavoring orange essence, always mix, subpackage.
Stripping curve assay method:
The dry suspension taking embodiment 1 ~ 4 and comparative example 1 ~ 3 gained respectively carries out stripping curve test.Dissolution medium is: the phosphate solution of the hydrochloric acid solution of pH1.2, the Acetate Solution of pH4.0, pH6.8 and purified water, medium volume: 900mL.Slurry processes, rotating speed: 50 revs/min.Test solution temperature: 37 ± 0.5 DEG C.UV determined wavelength: 240nm.Respectively at 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and sampling in 120 minutes 5 milliliters of tests, add synthermal isopyknic dissolution medium simultaneously.The results are shown in accompanying drawing 1 ~ 6.
PH value assay method:
Gauge: pH value analyzer (Mettler-Toledo, Inc.)
Measuring process: sample thief appropriate (about containing cefpodoxime 100mg), add purified water 10ml, after shake well, METHOD FOR CONTINUOUS DETERMINATION three pH value, average.
Determination of water method:
Gauge: karl Fischer formula moisture test apparatus (Wan Tong Instrument Ltd. of Switzerland)
Measuring process: sample thief appropriate (about moisture content 1mg), accurately weighed.Add in titration vessel from injection port, to be titrated complete after, record moisture value, METHOD FOR CONTINUOUS DETERMINATION twice, averages.
Content assaying method:
Test instrunment: high performance liquid chromatograph.Chromatographic condition: chromatographic column: Agilent Zorbax ODS post (4.6mm × 250mm, 5um), mobile phase: methanol: water (60:40), determined wavelength: 240nm, column temperature: 40 DEG C.
Mensuration process: get Cefpodoxime Proxetil reference substance appropriate, adds proper amount of methanol and dissolves, then is diluted to every 1ml about containing the solution of Cefpodoxime Proxetil 1mg with mobile phase, is reference substance solution.Separately get this product appropriate (being about equivalent to cefpodoxime 30mg), accurately weighed, put in 100ml volumetric flask, add proper amount of methanol and dissolve, then use mobile phase standardize solution, shake up, filter and be need testing solution.Get reference substance solution and need testing solution each 20ul injection liquid chromatography, record chromatogram, calculates cefpodoxime ester content by external standard method.
Determination of related substances method:
Test instrunment: high performance liquid chromatograph.Chromatographic condition: chromatographic column: Agilent Zorbax ODS post (4.6mm × 250mm, 5um), mobile phase: methanol: water (60:40), determined wavelength: 240nm, column temperature: 40 DEG C.
Mensuration process: get this product appropriate (being about equivalent to cefpodoxime 100mg), accurately weighed, put in 100ml volumetric flask, add proper amount of methanol and dissolve, then use mobile phase standardize solution, shake up, filter, be need testing solution.Precision measures need testing solution 1ml, puts in 100ml volumetric flask, uses mobile phase standardize solution, shakes up, in contrast product solution.Get reference substance solution and need testing solution each 20ul injection liquid chromatography, record chromatogram is to 2 times of Second principal component, peak retention time, and in need testing solution chromatogram, can ignore in any peak being less than contrast solution two main peak area and 0.1 times.
Accelerated test method:
Sample after packaging being put medicine stability investigates in proof box, and setting investigation condition is temperature 40 DEG C, relative humidity 75%, respectively at January, February, March and sampling in June, detects character, pH value, moisture, content and related substance.
Experimental result:
As shown in Figure 1, along with the increase of raw material and Surfactant Ratio, the dissolution of comparative example 2, embodiment 1 ~ 3 and each time point of comparative example 3 reduces gradually.5 minutes Dissolution Value of embodiment 1 and comparative example 2 are close to 90%, continue to increase dosage of surfactant to have little significance, 15 minutes Dissolution Value of embodiment 3 are close to 85%, 15 minutes Dissolution Value of comparative example 3 are less than 75%, therefore be 1:1 ~ 3:1 by the ratio-dependent of Cefpodoxime Proxetil and surfactant, to the dissolution improving this fast release solid formulation, there is significant beneficial effect.Although the 15min dissolution of embodiment 1,2 and comparative example 2 is all greater than 85%, but the dosage of surfactant of embodiment 2 is minimum, when being dissolved in dehydrated alcohol, the used time is also minimum, this is very useful in reducing production cost when commercially producing and enhancing productivity, and therefore preferably the ratio of Cefpodoxime Proxetil and surfactant is 1:2.
As shown in Figure 2, embodiment 2 and embodiment 4 stripping curve in purified water is almost consistent, therefore reaches a conclusion: use different wet granulation equipment not have a significant effect to result of extraction of the present invention.
From Fig. 3 ~ 6, the stripping curve of embodiment 2 in four kinds of different dissolution mediums is almost consistent, and 15 minutes dissolutions are all greater than 85%.The stripping curve of comparative example 1 in four kinds of different dissolution mediums is completely inconsistent, can only ensure that 15 minutes dissolutions are greater than 85% in pH1.2 hydrochloric acid medium, and 15 minutes dissolutions only have about 50% in pH4.0 acetate buffer, pH6.8 phosphate buffer and purified water medium, differ greatly with the result of extraction of the embodiment of the present invention, the prescription that the present invention adopts and the beneficial effect that technique is brought the dissolution improving this Cefpodoxime Proxetil fast release solid formulation are described.
Table 1 embodiment 2 accelerated test result
*: dissolution medium is: purified water, sample time is 30 minutes.
As seen from the above table, the sample of embodiment 2 is placed 6 months under Acceleration study condition, and character, pH value, moisture, dissolution and content have no significant change, and related substance slightly increases trend, but change not obvious, and sample stability is good.
Claims (8)
1. a Cefpodoxime Proxetil fast release solid formulation, containing Cefpodoxime Proxetil, surfactant, diluent, disintegrating agent, suspending agent and lubricant in said preparation, is characterized in that, each composition is by total formulation weight gauge:
2. fast release solid formulation as claimed in claim, is characterized in that, preferred each composition is by total formulation weight gauge:
3. fast release solid formulation as claimed in claim 1, it is characterized in that, said preparation is dry suspension or granule.
4. fast release solid formulation as claimed in claim 1, it is characterized in that, the weight ratio of surfactant and Cefpodoxime Proxetil is 1:1 ~ 1:3, preferred 1:2 ~ 1:3, more preferably 1:2.
5. fast release solid formulation as claimed in claim 1, it is characterized in that, in said preparation, surfactant is selected from non-ionic surface active agent, be selected from Tweens, spans, the mixture of one or more of polyoxyethylene apoplexy due to endogenous wind, it can be polysorbas20, polysorbate40, polysorbate60, Tween 80, polysorbate85, span 20, span 40, sorbester p18, sorbester p17, sorbester p37, polyoxyethylene castor oil, one or more mixture in polyoxyethylene hydrogenated Oleum Ricini and poloxamer, a kind of or both mixture in preferred polyoxyethylene castor oil and polyoxyethylene hydrogenated Oleum Ricini, more preferably polyoxyethylene hydrogenated Oleum Ricini.
6. fast release solid formulation as claimed in claim 1, it is characterized in that, diluent in described preparation to be selected from sucrose, Lactis Anhydrous, mannitol, soluble starch one or more mixture, one or both mixture in preferred Lactis Anhydrous and sucrose;
Disintegrating agent in this fast release solid formulation to be selected from low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethylcellulose calcium one or more mixture, preferably carboxymethyl cellulose calcium;
Suspending agent in this fast release solid formulation to be selected from hyprolose, hypromellose, polyvidone, sodium carboxymethyl cellulose and xanthan gum one or more mixture, preferred xanthan gum;
Lubricant agent in this fast release solid formulation is selected from the mixture of one or more in silicon dioxide, Pulvis Talci, magnesium stearate, stearic acid, Polyethylene Glycol, sodium stearyl fumarate, Glyceryl Behenate and hydrogenated vegetable oil, preferably talc powder.
Also containing correctives in this fast release solid formulation, correctives is the mixture of acidity regulator and essence.Acidity regulator is selected from the mixture of one or more in citric acid, malic acid, tartaric acid, preferably citric acid; Essence is selected from the mixture of one or more in flavoring banana essence, flavoring orange essence, Fructus Citri Limoniae essence, peach flavor, cream flavour, chocolate essence, strawberry essence, flavoring pineapple essence, apple essence, kiwi flavor, grape essence, watermelon essence, Hami melon essence, preferred flavoring orange essence.
7. prepare the method for the fast release solid formulation of any one in claim 1 ~ 6, it is characterized in that, preparation technology is wet granulation, and concrete operations are:
(1) Cefpodoxime Proxetil and surfactant are dissolved in dehydrated alcohol, obtain mixture one;
(2) by after diluent and disintegrating agent mix homogeneously, slowly add or spray into mixture one, granulate, fluid bed 30 DEG C of dryings, obtain mixture two;
(3) in mixture two, add suspending agent, correctives and lubricant, always mix, subpackage.
8. prepare the method for the fast release solid formulation of any one in claim 1 ~ 7, the equipment that wherein wet granulation step uses is wet mixing pelletizer or fluid bed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510163430.XA CN104771368B (en) | 2015-04-08 | 2015-04-08 | Cefpodoxime Proxetil quick releasing formulation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510163430.XA CN104771368B (en) | 2015-04-08 | 2015-04-08 | Cefpodoxime Proxetil quick releasing formulation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104771368A true CN104771368A (en) | 2015-07-15 |
| CN104771368B CN104771368B (en) | 2017-12-22 |
Family
ID=53613358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510163430.XA Active CN104771368B (en) | 2015-04-08 | 2015-04-08 | Cefpodoxime Proxetil quick releasing formulation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104771368B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113456599A (en) * | 2020-03-30 | 2021-10-01 | 洛阳惠中兽药有限公司 | Preparation method of cefpodoxime proxetil tablets and cefpodoxime proxetil tablets prepared by same |
| CN113817440A (en) * | 2020-06-18 | 2021-12-21 | 中国石油化工股份有限公司 | Compound hydrate accelerant, application and gas storage and transportation method |
| CN115813868A (en) * | 2022-12-06 | 2023-03-21 | 江西省保灵动物保健品有限公司 | High-dissolution cefpodoxime proxetil tablet and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1505515A (en) * | 2001-02-27 | 2004-06-16 | ʵ | Oral pharmaceutical composition of cefpodoxime proxetil |
| CN101011360A (en) * | 2007-02-05 | 2007-08-08 | 深圳致君制药有限公司 | Recipe composition of dry turbid agent and its preparation process |
| CN102525948A (en) * | 2012-01-17 | 2012-07-04 | 山东罗欣药业股份有限公司 | Dry suspension of cefpodoxime proxetil composition and preparation method thereof |
| CN103230367A (en) * | 2013-05-07 | 2013-08-07 | 山东罗欣药业股份有限公司 | Cefpodoxime proxetil composition dry suspension and preparation method thereof |
| CN103301068A (en) * | 2013-07-08 | 2013-09-18 | 广东彼迪药业有限公司 | Cefixime dry suspension and preparation method thereof |
-
2015
- 2015-04-08 CN CN201510163430.XA patent/CN104771368B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1505515A (en) * | 2001-02-27 | 2004-06-16 | ʵ | Oral pharmaceutical composition of cefpodoxime proxetil |
| CN101011360A (en) * | 2007-02-05 | 2007-08-08 | 深圳致君制药有限公司 | Recipe composition of dry turbid agent and its preparation process |
| CN102525948A (en) * | 2012-01-17 | 2012-07-04 | 山东罗欣药业股份有限公司 | Dry suspension of cefpodoxime proxetil composition and preparation method thereof |
| CN103230367A (en) * | 2013-05-07 | 2013-08-07 | 山东罗欣药业股份有限公司 | Cefpodoxime proxetil composition dry suspension and preparation method thereof |
| CN103301068A (en) * | 2013-07-08 | 2013-09-18 | 广东彼迪药业有限公司 | Cefixime dry suspension and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113456599A (en) * | 2020-03-30 | 2021-10-01 | 洛阳惠中兽药有限公司 | Preparation method of cefpodoxime proxetil tablets and cefpodoxime proxetil tablets prepared by same |
| CN113817440A (en) * | 2020-06-18 | 2021-12-21 | 中国石油化工股份有限公司 | Compound hydrate accelerant, application and gas storage and transportation method |
| CN113817440B (en) * | 2020-06-18 | 2022-11-08 | 中国石油化工股份有限公司 | Compound hydrate accelerant, application and gas storage and transportation method |
| CN115813868A (en) * | 2022-12-06 | 2023-03-21 | 江西省保灵动物保健品有限公司 | High-dissolution cefpodoxime proxetil tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104771368B (en) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2785857C (en) | Production method of solid preparations and the solid preparations produced by the method | |
| CN103417512B (en) | A kind of Biomox and preparation method thereof | |
| CN104666262B (en) | A kind of razaxaban piece | |
| JPH0819003B2 (en) | Nucleated granule and method for producing the same | |
| CN104771368A (en) | Cefpodoxime proxetil rapid-release preparation and preparation method thereof | |
| CN106943367B (en) | Afatinib maleate tablet and preparation method thereof | |
| CN103717209A (en) | Prasugrel-containing immediate release stable oral pharmaceutical compositions | |
| CN105343028A (en) | Medicine composition with norfloxacin and method for preparing medicine composition | |
| CN105085549A (en) | Cefaclor compound, medicine composition of cefaclor compound and bromhexine hydrochloride, and preparation of cefaclor compound | |
| CN109908104B (en) | Amoxicillin capsule and preparation method thereof | |
| CN106860404A (en) | A kind of sildenafil citrate taste masking resin complexes and its application | |
| WO2012088992A1 (en) | Process for preparing solid medicine preparation and solid medicine preparation therefrom | |
| WO2011079764A1 (en) | Solid formulation of eszopiclone and the preparation method thereof | |
| CN103417535B (en) | A kind of amoxicillin and clavulanate potassium tablets and preparation method thereof | |
| CN112546018A (en) | Cefaclor capsule and preparation method thereof | |
| CN102058602B (en) | Stable oral solid preparation containing losartan potassium and hydrochlorothiazide | |
| CN106310286B (en) | Tosufloxacin tosylate composition | |
| US20130115253A1 (en) | Sustained Release Suspension Preparation For Dextromethorphan | |
| CN115364059B (en) | Cefpodoxime proxetil particles and preparation method thereof | |
| CN114652688B (en) | Montelukast sodium chewable tablet and preparation method thereof | |
| CN103948562A (en) | Desloratadine capsule and preparation method thereof | |
| CN115590832B (en) | Faropenem sodium tablet and preparation method thereof | |
| CN103462929B (en) | A kind of Amphocaps and preparation method thereof | |
| CN112336711B (en) | Glucozine lysine orally disintegrating tablet | |
| CN104644601A (en) | Capecitabine tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 050035 No. 518, Huai'an East Road, high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Patentee after: SHIJIAZHUANG NO.4 PHARMACEUTICAL Co.,Ltd. Address before: 050035 No.288, Zhujiang Avenue, Shijiazhuang hi tech Industrial Development Zone, Shijiazhuang City, Hebei Province Patentee before: SHIJIAZHUANG NO.4 PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |